BHP collaborates with Chinese steel producer to address climate change

Multinational commodities giant BHP has signed a memorandum of understanding (MoU) with steel producer China Baowu to focus on reducing greenhouse gas (GHG) emissions in the steel industry. As part of the MoU, the two firms have launched a five-year partnership to invest $35m in developing low carbon technologies.

Canterra Minerals to acquire Teton Opportunities

Canterra Minerals Corporation, a Canadian resource company specializing in diamond exploration within the Northwest Territories, has entered into a binding share exchange agreement to acquire all of the issued and outstanding securities of Teton Opportunities Inc., a private, arm’s-length British Columbia company that holds an option with a subsidiary of Altius Minerals Corp. to acquire the Wilding Lake Project located in central Newfoundland, Canada.

JX Nippon to buy out Caserones copper mine in Chile

Japanese firm JX Nippon Mining & Metals has signed an agreement to buy out the stake in the Caserones copper mine owned by its partners Mitsui & Co and Mitsui Mining and Smelting for an undisclosed consideration.

The mine is located in northern Chile, close to the border with Argentina.

Cross River Ventures to acquire Northern Dominion Metals

Cross River Ventures Corp, a gold and silver exploration company, has agreed to acquire all of the outstanding shares of Northern Dominion Metals Corporation, a mineral exploration company which holds rights to acquire interests in a series of gold exploration projects, from Gravel Ridge Resources Ltd, Bounty Gold Corp, and Perry English. 

Melior Resources to acquire 100% stake in Ranchero Gold

Melior Resources Inc. a Canada-based company invests in mining, metallurgical, and mineral companies, has announced plans to acquire 100% stake in Ranchero Gold Corp., a Mexico-based company that holds gold exploration property.

Rhizen signs oncology drug development deal with Curon

Swiss biopharma company Rhizen Pharmaceuticals has signed an exclusive licensing agreement with Curon Biopharmaceutical to develop and commercialise Tenalisib for oncology in the Greater China region. Tenalisib, a highly selective dual PI3K delta and gamma inhibitor, is currently in Phase II clinical development for haematological malignancies. The US FDA granted fast track and orphan drug designations for the drug candidate Tenalisib as a treatment for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.